Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception

Objective - Combined oral contraceptives induce a reversible hypercoagulable state with an enhanced risk of venous thromboembolism, but the underlying mechanism(s) remain unclear. Subjects on combined oral contraceptives also demonstrate a characteristic resistance to APC (activated protein C) in th...

Full description

Bibliographic Details
Main Authors: Tanratana, P., Ellery, Paul, Westmark, P., Mast, A., Sheehan, J.
Format: Journal Article
Published: Lippincott Williams & Wilkins 2018
Online Access:http://hdl.handle.net/20.500.11937/61201
_version_ 1848760667177222144
author Tanratana, P.
Ellery, Paul
Westmark, P.
Mast, A.
Sheehan, J.
author_facet Tanratana, P.
Ellery, Paul
Westmark, P.
Mast, A.
Sheehan, J.
author_sort Tanratana, P.
building Curtin Institutional Repository
collection Online Access
description Objective - Combined oral contraceptives induce a reversible hypercoagulable state with an enhanced risk of venous thromboembolism, but the underlying mechanism(s) remain unclear. Subjects on combined oral contraceptives also demonstrate a characteristic resistance to APC (activated protein C) in the thrombin generation assay. Here, we report the potential role of plasma factor IXa (FIXa) as a mechanism for hormone-induced systemic hypercoagulability. Approach and Results - A novel assay was used to determine FIXa activity in plasma samples from volunteer blood donors. Plasma from 36 premenopausal females on hormonal contraception and 35 not on hormonal contraception, 35 postmenopausal females, and 10 males were analyzed for FIXa activity, total PS (protein S), total tissue factor pathway inhibitor (TFPI), and TFPI-a antigen. Premenopausal females on hormonal contraception demonstrated significantly increased FIXa activity and decreased TFPI-a compared with the other groups. Remarkably, FIXa values were not normally distributed in the hormonal contraception group, but skewed toward the high end. Plasma FIXa activity inversely correlated with both TFPI-a and total PS antigen. Ex vivo determination of TF-dependent FIX activation in FV-deficient plasma demonstrated that inhibitory anti-TFPI antibodies enhanced FIXa generation by 2- to 3-fold, whereas addition of 75 nmol/L PS reduced FIXa generation by ˜2-fold. Further, increasing FIXa concentration enhanced APC resistance during TF-triggered plasma thrombin generation. Conclusions - Elevation of plasma FIXa activity in association with reductions in TFPI-a and PS is a potential mechanism for systemic hypercoagulability and resistance to APC in premenopausal females on hormonal contraception.
first_indexed 2025-11-14T10:19:25Z
format Journal Article
id curtin-20.500.11937-61201
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T10:19:25Z
publishDate 2018
publisher Lippincott Williams & Wilkins
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-612012018-04-16T00:17:13Z Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception Tanratana, P. Ellery, Paul Westmark, P. Mast, A. Sheehan, J. Objective - Combined oral contraceptives induce a reversible hypercoagulable state with an enhanced risk of venous thromboembolism, but the underlying mechanism(s) remain unclear. Subjects on combined oral contraceptives also demonstrate a characteristic resistance to APC (activated protein C) in the thrombin generation assay. Here, we report the potential role of plasma factor IXa (FIXa) as a mechanism for hormone-induced systemic hypercoagulability. Approach and Results - A novel assay was used to determine FIXa activity in plasma samples from volunteer blood donors. Plasma from 36 premenopausal females on hormonal contraception and 35 not on hormonal contraception, 35 postmenopausal females, and 10 males were analyzed for FIXa activity, total PS (protein S), total tissue factor pathway inhibitor (TFPI), and TFPI-a antigen. Premenopausal females on hormonal contraception demonstrated significantly increased FIXa activity and decreased TFPI-a compared with the other groups. Remarkably, FIXa values were not normally distributed in the hormonal contraception group, but skewed toward the high end. Plasma FIXa activity inversely correlated with both TFPI-a and total PS antigen. Ex vivo determination of TF-dependent FIX activation in FV-deficient plasma demonstrated that inhibitory anti-TFPI antibodies enhanced FIXa generation by 2- to 3-fold, whereas addition of 75 nmol/L PS reduced FIXa generation by ˜2-fold. Further, increasing FIXa concentration enhanced APC resistance during TF-triggered plasma thrombin generation. Conclusions - Elevation of plasma FIXa activity in association with reductions in TFPI-a and PS is a potential mechanism for systemic hypercoagulability and resistance to APC in premenopausal females on hormonal contraception. 2018 Journal Article http://hdl.handle.net/20.500.11937/61201 10.1161/ATVBAHA.117.309919 Lippincott Williams & Wilkins restricted
spellingShingle Tanratana, P.
Ellery, Paul
Westmark, P.
Mast, A.
Sheehan, J.
Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception
title Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception
title_full Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception
title_fullStr Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception
title_full_unstemmed Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception
title_short Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception
title_sort elevated plasma factor ixa activity in premenopausal women on hormonal contraception
url http://hdl.handle.net/20.500.11937/61201